Clinical trials: Ovary Disease
Ovarian Cancer
Ovarian Cancer Individualized Scoring System Scoring System
This project aims at creating an individualized prognostic model using patient characteristics and disease features to determine disease prognosis using machine learning technology.
- Trial name
- OCISS (NCT05496517)
- Where
- 2 sites in Egypt
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Assiut University
Ovarian Hyperstimulation Syndrome
Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers
The purpose of this study is to determine whether cabergoline is effective in reducing the incidence and severity of Ovarian Hyperstimulation Syndrome (OHSS), especially for severe cases; and to derive biomarkers for the risk of…
- Trial name
- NCT01535859
- Testing
- Cabergoline
- Where
- Singapore
- Volunteers
- 46 people
- Sponsor
- KK Women's and Children's Hospital
Ovarian Cancer
Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer
The purpose of this study is to validate a score developed by the AGO-OVAR for complete resection of the tumor
- Trial name
- NCT00368420
- Where
- 12 sites in Austria, Belgium and 2 more
- Volunteers
- 122 people
- Sponsor
- AGO Study Group
Metastatic Ovarian Cancer, Triple Negative Breast Cancer
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
This is a Phase 1b, open-label, non-randomized, Dose Confirmation study. Subjects will be treated, once a week, with IV doses of Nerofe and low dose (20 mg/m2) Doxorubicin (6-8 hours from one another) in consecutive, 28-day…
- Trial name
- NCT03634150
- Testing
- Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.
- Where
- Israel
- Sponsor
- Immune System Key Ltd
Polycystic Ovary Syndrome
Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)
The aim to evaluate whether activation of the hypothalamic-pituitary-gonadal axis in PCOS is associated with transient microstructural and metabolic changes in the female hypothalamus using MRI approaches to assess water…
- Trial name
- MRI-PCOS (NCT03043924)
- Testing
- Cyproterone Acetate + estradiol, Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet
- Where
- France
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Ovarian Cancer, Sarcoma
Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma
Phase II trial to study the effectiveness of dolastatin 10 in treating patients who have recurrent or metastatic soft tissue sarcoma.
- Trial name
- NCT00003778
- Testing
- dolastatin 10
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Polycystic Ovary Syndrome (PCOS)
Promotion of a Standardized Diagnostic and Treatment Pathway for Polycystic Ovary Syndrome Based on a Bidirectional Referral System
The goal of this clinical trial is to: 1. promote and optimize standardized diagnostic and treatment pathways for polycystic ovary syndrome (PCOS) and to investigate the clinical phenotypic characteristics of PCOS; 2.
- Trial name
- NCT07350876
- Testing
- Standardized Diagnostic and Treatment Pathways for PCOS + Lifestyle Intervention + Prebiotic Supplementation, Standardized Diagnostic and Treatment Pathways for PCOS + Lifestyle Intervention
- Where
- China
- Volunteers
- 227 people
- Sponsor
- Xuanwu Hospital, Beijing
Ovarian Cancer
Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer
The primary objective of this study is to compare the time to progressive disease in patients treated with gemcitabine plus carboplatin versus carboplatin monotherapy.
- Trial name
- NCT00102414
- Testing
- Gemcitabine
- Volunteers
- 356 people
- Sponsor
- AGO Study Group
Ovarian Cancer, Cervical Cancer
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of…
- Trial name
- NCT06251947
- Testing
- Efbemalenograstim Alfa
- Where
- 6 sites in China
- Volunteers
- 83 people
- Sponsor
- Shandong University
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Ovarian Cancer
A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
This study is an open-label, single-Arm， phase II clinical trial of a Chinese Patent Medicine Yangzheng Xiaoji Capsule to improve the adverse reaction nausea of Niraparib in the first-line maintenance treatment in advanced…
- Trial name
- NCT05641506
- Testing
- Yangzheng Xiaoji, Niraparib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Ovarian Hyperstimulation Syndrome
Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation Patients
The aim of the study is to determine serum oxidative stress status by ischemia modified albumin (IMA), total antioxidant capacity (TAC), total oxidative capacity (TOS), oxidative stress capacity (OSI), and serum malondialdehyde…
- Trial name
- NCT02202278
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Karadeniz Technical University
Epithelial Ovarian Cancer
Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward
Ovarian cancer is the most lethal gynecologic malignancy. The majority of patients get diagnosed with advanced disease with peritoneal dissemination.It has been demonstrated that the addition of Hyperthermic Intraperitoneal…
- Trial name
- GARD-HIPEC (NCT06277947)
- Testing
- China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Cancer
Mesenchymal Stem Cells (MSC) for Ovarian Cancer
The goal of this clinical research study is to find the highest tolerable dose of human mesenchymal stem cells with interferon beta (MSC-INFb) that can be given to patients with ovarian cancer and to test the safety of the…
- Trial name
- NCT02530047
- Testing
- MSC-INFβ, Questionnaires
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
First Recurrence of Ovarian Cancer
Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence
The purpose of this study is to determine the role of surgery followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) versus surgery alone in patients with platinum-sensitive first recurrence of ovarian cancer.
- Trial name
- HORSE (NCT01539785)
- Testing
- Secondary citoreduction, Hyperthermic intra-peritoneal chemotherapy (HIPEC)
- Where
- Italy
- Volunteers
- 158 people
- Sponsor
- Catholic University of the Sacred Heart
Ovarian Neoplasm, Cancer Genetics
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
Background: Certain genetic mutations are linked to higher rates of cancer. It is important for people with these mutations to tell their families about it.
- Conditions
- Ovarian Neoplasm, Cancer Genetics, Breast Cancer
- Trial name
- NCT01374685
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
A Survivorship Care Plan for Gynaecological Cancer Patients
After treatment women surviving gynaecological cancer may experience lateeffects and longterm challenges specific to their disease and treatment resulting in functional deficits and a reduction in societal integration (Yabroff et…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01582906
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Ovarian Cancer
Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer
This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit…
- Trial name
- KELI-PAOLA (NCT06660147)
- Where
- 24 sites in France, Monaco
- Volunteers
- 243 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Neoplasms, Uterine Neoplasms
Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology
Study Title Group Dynamics Evaluation in Gynecologic Multidisciplinary Tumor Boards - GOLD Study Background and Rationale Multidisciplinary Tumor Boards are central to complex oncologic decision-making.
- Trial name
- GOLD (NCT07645716)
- Testing
- Online Survey Assessment of Tumor Board Group Dynamics
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Genital Diseases, Female, Ovarian Neoplasms
Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients
The purpose of this study is to determine whether HGF serum concentration might be raised in vivo by administering nadroparin given with prophylactic purpose to gynecological patients.
- Conditions
- Genital Diseases, Female, Ovarian Neoplasms, Urogenital Neoplasms
- Trial name
- NCT01523652
- Where
- Italy
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.